
JHVEPhoto | BigStock.com
The U.S. Food and Drug Administration (FDA) is suspending efforts to improve testing for highly pathogenic avian influenza (HPAI) due to staffing cuts throughout the Department of Health and Human Services (HHS), according to a Reuters report.